We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent (A) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y
Read MoreHide Full Article
Agilent Technologies (A - Free Report) has delivered third-quarter fiscal 2024 earnings of $1.32 per share, which beat the Zacks Consensus Estimate by 5.6%. However, the bottom line decreased 8% from the year-ago quarter.
Revenues of $1.58 billion beat the Zacks Consensus Estimate of $1.56 billion. The top line declined 5.6% on a reported basis and 4.4% on a core basis from the year-ago quarter.
The decline was attributed to broad-based weakness across the Pharma, Food, Chemical and Advanced Materials, and Academic and Government markets.
Weak momentum in China was another concern.
Nevertheless, the company witnessed improvements in the Diagnostics and Clinical, and Environmental and Forensics markets in the reported quarter.
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Agilent has three reporting segments — Life Sciences & Applied Markets Group (“LSAG”), Agilent Cross Lab Group (“ACG”), and Diagnostics and Genomics Group (“DGG”).
LSAG: The segment accounted for $782 million or 50% of the company’s total revenues, down 8% on a reported basis and 7% on a core basis from the prior-year quarter. This was due to softness in the instrument business, and weakening momentum across all the geographic regions and end markets, except for Environmental and Forensics. The reported figure beat the Zacks Consensus Estimate of $755 million.
ACG: Revenues from the segment were $411 million, accounting for 26% of the total revenues. The figure surpassed the consensus mark of $410 million. The top line improved 4% from the prior-year quarter on a reported basis and rose 5% on a core basis. This was driven by strong growth in service contract revenues. Growing momentum across all geographic regions, except for China, was a positive.
DGG: Revenues decreased 9% year over year on a reported and 8% on a core basis to $385 million, accounting for the remaining 24% of the total revenues. The figure missed the consensus mark of $405 million. Sluggishness in Genomics, Cell Analysis and NASD was concerning.
Operating Results
For the fiscal third quarter, the gross margin in the LSAG segment expanded by 10 basis points (bps) to 60.2% from the prior-year quarter. ACG’s gross margin expanded by 120 bps to 52.1%. DGG’s gross margin contracted 170 bps year over year to 51.8%.
Research and development (“R&D”) expenses were $127 million, up 7.6% from the prior-year quarter. Selling, general and administrative (“SG&A”) expenses were $395 million, down 2.9% from the year-earlier quarter. As a percentage of revenues, R&D expenses expanded by 90 bps year over year to 8%, whereas SG&A expenses increased 70 bps year over year to 25%.
The operating margin for the fiscal third quarter was 21.1%, which expanded significantly from 7.9% in the year-earlier quarter.
Segment-wise, the operating margin in the LSAG segment contracted by 260 bps to 28.4% from the prior-year quarter. ACG’s operating margin expanded by 130 bps year over year to 34%. DGG’s operating margin contracted 440 bps year over year to 18.3%.
Balance Sheet
As of Jul 31, 2024, Agilent’s cash and cash equivalents were $1.78 billion, up from $1.67 billion as of Apr 30, 2024.
Accounts receivables were $1.23 billion at the end of third-quarter fiscal 2024 compared with $1.25 billion at the end of second-quarter fiscal 2024.
The long-term debt was $2.137 billion for the reported quarter compared with $2.136 billion in the prior quarter.
Guidance
For the fourth quarter of fiscal 2024, management expects revenues of $1.641-$1.691 billion, suggesting a decline of 2.8% to an increase of 0.2% on a reported basis and a decrease of 1.9% to a rise of 1.1% on a core basis from the year-ago quarter’s actuals. The Zacks Consensus Estimate for revenues is pegged at $1.67 billion.
Non-GAAP fiscal fourth-quarter earnings per share are expected to be $1.38-$1.42. The consensus mark for the same is pinned at $1.43.
For fiscal 2024, management revised its revenue guidance from $6.42-$6.50 billion to $6.45-6.50 billion, implying a fall of 5.6-4.9% on a reported basis and 5-4.3% on a core basis from the fiscal 2023 reported figure. The Zacks Consensus Estimate for the same is pegged at $6.46 billion.
The company also revised fiscal 2024 non-GAAP earnings per share guidance from $5.15-$5.25 to $5.21-5.25. The consensus mark for fiscal 2024 earnings is pinned at $5.19 per share.
Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #4 (Sell).
Image: Bigstock
Agilent (A) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y
Agilent Technologies (A - Free Report) has delivered third-quarter fiscal 2024 earnings of $1.32 per share, which beat the Zacks Consensus Estimate by 5.6%. However, the bottom line decreased 8% from the year-ago quarter.
Revenues of $1.58 billion beat the Zacks Consensus Estimate of $1.56 billion. The top line declined 5.6% on a reported basis and 4.4% on a core basis from the year-ago quarter.
The decline was attributed to broad-based weakness across the Pharma, Food, Chemical and Advanced Materials, and Academic and Government markets.
Weak momentum in China was another concern.
Nevertheless, the company witnessed improvements in the Diagnostics and Clinical, and Environmental and Forensics markets in the reported quarter.
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Agilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. Quote
Segmental Top-Line Details
Agilent has three reporting segments — Life Sciences & Applied Markets Group (“LSAG”), Agilent Cross Lab Group (“ACG”), and Diagnostics and Genomics Group (“DGG”).
LSAG: The segment accounted for $782 million or 50% of the company’s total revenues, down 8% on a reported basis and 7% on a core basis from the prior-year quarter. This was due to softness in the instrument business, and weakening momentum across all the geographic regions and end markets, except for Environmental and Forensics. The reported figure beat the Zacks Consensus Estimate of $755 million.
ACG: Revenues from the segment were $411 million, accounting for 26% of the total revenues. The figure surpassed the consensus mark of $410 million. The top line improved 4% from the prior-year quarter on a reported basis and rose 5% on a core basis. This was driven by strong growth in service contract revenues. Growing momentum across all geographic regions, except for China, was a positive.
DGG: Revenues decreased 9% year over year on a reported and 8% on a core basis to $385 million, accounting for the remaining 24% of the total revenues. The figure missed the consensus mark of $405 million. Sluggishness in Genomics, Cell Analysis and NASD was concerning.
Operating Results
For the fiscal third quarter, the gross margin in the LSAG segment expanded by 10 basis points (bps) to 60.2% from the prior-year quarter. ACG’s gross margin expanded by 120 bps to 52.1%. DGG’s gross margin contracted 170 bps year over year to 51.8%.
Research and development (“R&D”) expenses were $127 million, up 7.6% from the prior-year quarter. Selling, general and administrative (“SG&A”) expenses were $395 million, down 2.9% from the year-earlier quarter. As a percentage of revenues, R&D expenses expanded by 90 bps year over year to 8%, whereas SG&A expenses increased 70 bps year over year to 25%.
The operating margin for the fiscal third quarter was 21.1%, which expanded significantly from 7.9% in the year-earlier quarter.
Segment-wise, the operating margin in the LSAG segment contracted by 260 bps to 28.4% from the prior-year quarter. ACG’s operating margin expanded by 130 bps year over year to 34%. DGG’s operating margin contracted 440 bps year over year to 18.3%.
Balance Sheet
As of Jul 31, 2024, Agilent’s cash and cash equivalents were $1.78 billion, up from $1.67 billion as of Apr 30, 2024.
Accounts receivables were $1.23 billion at the end of third-quarter fiscal 2024 compared with $1.25 billion at the end of second-quarter fiscal 2024.
The long-term debt was $2.137 billion for the reported quarter compared with $2.136 billion in the prior quarter.
Guidance
For the fourth quarter of fiscal 2024, management expects revenues of $1.641-$1.691 billion, suggesting a decline of 2.8% to an increase of 0.2% on a reported basis and a decrease of 1.9% to a rise of 1.1% on a core basis from the year-ago quarter’s actuals. The Zacks Consensus Estimate for revenues is pegged at $1.67 billion.
Non-GAAP fiscal fourth-quarter earnings per share are expected to be $1.38-$1.42. The consensus mark for the same is pinned at $1.43.
For fiscal 2024, management revised its revenue guidance from $6.42-$6.50 billion to $6.45-6.50 billion, implying a fall of 5.6-4.9% on a reported basis and 5-4.3% on a core basis from the fiscal 2023 reported figure. The Zacks Consensus Estimate for the same is pegged at $6.46 billion.
The company also revised fiscal 2024 non-GAAP earnings per share guidance from $5.15-$5.25 to $5.21-5.25. The consensus mark for fiscal 2024 earnings is pinned at $5.19 per share.
Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader technology sector are Arista Networks (ANET - Free Report) , Audioeye (AEYE - Free Report) and Badger Meter (BMI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Arista Networks’ shares have gained 49.5% in the year-to-date period. The long-term earnings growth rate for ANET is anticipated to be 17.20%.
Audioeye’s shares have surged 331.6% in the year-to-date period. The long-term earnings growth rate for Audioeye is projected at 25%.
Badger Meter’s shares have gained 31.8% in the year-to-date period. The long-term earnings growth rate for Badger Meter is expected to be 17.91%.